ライフサイエンスコーパス: per minute

1 mug/kg per minute), and high-dose (>5 mug/kg per minute).

2 6) compared with controls (16.7+/-1.37 mL/kg per minute).

3 and tachycardia (mean heart rate, >93 beats per minute).

4 d rest (4-6 minutes IV adenosine, 140 mug/kg per minute).

5 ion with traffic density (number of vehicles per minute).

6 rates (98.6+/-19.4 versus 112.0+/-20.3 beats per minute).

7 acquired d6-alpha-T (21 +/- 2 nmol/L plasma per minute).

8 nd a lower stress MBF (1.76 versus 2.36 mL/g per minute).

9 of sedentary physical activity (<320 counts per minute).

10 iscrimination for rates >=200 and <250 beats per minute.

11 logical pacemaker rates were 45 and 75 beats per minute.

12 onditions at stimulation rates of 60 and 180 per minute.

13 demonstrated normal sinus rhythm at 73 beats per minute.

14 alysis with throughput of about four samples per minute.

15 nts made between 0 and 3 positive utterances per minute.

16 , and vascular resistance 153 +/- 16 mm Hg/L per minute.

17 rminus (>2 megabases) at rates >50 kilobases per minute.

18 d the mean single-nephron GFR was 80+/-40 nl per minute.

19 mm Hg or a heart rate greater than 120 beats per minute.

20 c chronotropic response upon tilt > 10 beats per minute.

21 ated creatinine clearance of more than 60 mL per minute.

22 placement, at the equivalent of two letters per minute.

23 ughput of over 1.95 x 10(6) reads classified per minute.

24 men with resting heart rates below 62 beats per minute.

25 /- 3.2 with median 0 (range, -8 to 17) beats per minute.

26 rmational change at rates of up to one cycle per minute.

27 ated creatinine clearance of more than 60 mL per minute.

28 ute to a minimum of 8500 +/- 380 revolutions per minute.

29 were superfused and stimulated at 100 beats per minute.

30 8 (95% confidence interval: 0.04, 1.92) beat per minute.

31 chieve a target heart rate of 55 to 60 beats per minute.

32 037 individuals who took 82.9 to 149.5 steps per minute.

33 tests when sinus rate exceeded 99+/-17 beats per minute.

34 tachycardia with a median rate of 230 beats per minute.

35 rable neurological outcome decreased by 1.2% per minute.

36 incrementally until HR increased by 30 beats per minute.

37 a CIED with heart rates as high as 102 beats per minute.

38 a CIED with heart rates as high as 102 beats per minute.

39 hile maintaining a false alarm rate of 0.014 per minute.

40 p)ppApp at rates of nearly 180,000 molecules per minute.

41 generate polymers at a rate of tens of grams per minute.

42 rate changes of up to approximately 10 beats per minute.

43 apidly by blind participants, up to 86 forms per minute.

44 age oxygen consumption was 1.1 +/- 0.2 mL/kg per minute.

45 tching beats from 35+/-4.3 to 65+/-4.0 beats per minute.

46 /mL collagen -33.8x10(2)+/-12.4x10(2) counts per minute; 0.5 mg/mL collagen -67.7x10(2)+/-37.4x10(2)

47 1.72, 1.19-2.49); and heart rate 60-90 beats per minute (1.21, 0.89-1.63) and >/=90 beats per minute

48 +/- standard deviation PF was 18.9 mL/100 mL per minute +/- 11.0 and mean MTT was 213.3 seconds +/- 5

49 ental doses (50 mug/kg per minute, 80 mug/kg per minute, 110 mug/kg per minute, and 140 mug/kg per mi

50 1080 individuals who took 18.5 to 56.0 steps per minute; 12.6 per 1000 person-years (207 deaths) for

51 dard deviation) in the AF group and 63 beats per minute +/- 14 in the SR group (P < .01).

52 per minute (1.21, 0.89-1.63) and >/=90 beats per minute (2.35, 1.03-5.33).

53 ially tested in a euthanized pig at 60 beats per minute, 2 V amplitude, and 1 ms pulse width, restori

54 less during play with electronic toys (mean per minute, 2.9; 95% CI, 2.16-3.69) than during play wit

55 Mean heart rate during scanning was 83 beats per minute +/- 21 (standard deviation) in the AF group a

56 2.16-3.69) than during play with books (mean per minute, 3.91; 95% CI, 3.09-4.68).

57 ower during play with traditional toys (mean per minute, 4.09; 95% CI, 3.26-4.99) than during play wi

58 ords during play with traditional toys (mean per minute, 55.56; 95% CI, 46.49-64.17) than during play

59 3.26-4.99) than during play with books (mean per minute, 6.96; 95% CI, 6.07-7.97).

60 1153 individuals who took 56.1 to 69.2 steps per minute; 6.8 per 1000 person-years (124 deaths) for t

61 tion of N2 into NH3 The turnover rate was 75 per minute, 63% of the ATP-coupled reaction rate for the

62 .49-64.17) than during play with books (mean per minute, 66.89; 95% CI, 59.93-74.19) and use of conte

63 eline and under incremental doses (50 mug/kg per minute, 80 mug/kg per minute, 110 mug/kg per minute,

64 by 7.02 mumol per kilogram of fat-free mass per minute (95% CI, 3.21 to 10.84) in the surgery group

65 by 7.04 mumol per kilogram of fat-free mass per minute (95% confidence interval [CI], 4.74 to 9.33)

66 uptake (weighted mean difference, 1.8 mL/kg per minute; 95% confidence interval, 1.4-2.3), pulmonary

67 ed with higher adenoma detection rates (3.6% per minute; 95% confidence interval: 2.4% to 4.8%; P < .

68 degrees C, a respiratory rate of 48 breaths per minute, a heart rate of 158 beats per minute, decrea

69 ted heart rates, rising as much as 123 beats per minute above the pre-flight baseline.

70 nute) and PDE3-specific (48.2+/-15.9 pmol/mg per minute) activities in comparison with those of nonfa

71 sociated with NSVT runs at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence

72 max rose from 40.3+/-1.6 to 48.7+/-2.5 mL/kg per minute after 1 year (P<0.00001), associated with an

73 )-alkylates indoles with up to 470 turnovers per minute and 18 000 total turnovers.

74 stimated initial rate of over 1000 turnovers per minute and can be used under aerobic conditions.

75 up-regulation (stroke frequency >25 strokes per minute and energetic costs three to six times the re

76 Such transients average approximately two per minute and last approximately 30 s.

77 based therapy delivery for rates >=250 beats per minute and morphology discrimination for rates >=200

78 The data are logged up to 12 samples per minute and postprocessed using custom Matlab scripts

79 g was performed by pacing the right PN at 60 per minute and recording diaphragmatic compound motor ac

80 increase in heart rate was 23.9+/-11.4 beats per minute and the mean decreases in systolic and diasto

81 es at a data acquisition rate of over 6 EEMs per minute and with a spectral resolution of 5.3 nm.

82 erformed during adenosine stress (140 mug/kg per minute) and at rest on a Siemens 1.5-T Avanto scanne

83 93 (HEK) (Km 3.8 microM and Vmax 307 pmol/mg per minute) and HeLa (Km 0.32 microM and Vmax 42 pmol/mg

84 IV, sinus rhythm, and heart rate >/=70 beats per minute) and non-SHIFT type.

85 gher total PDE-specific (74.6+/-13.8 pmol/mg per minute) and PDE3-specific (48.2+/-15.9 pmol/mg per m

86 arts consumed oxygen (0.09 +/- 0.01 mL/100 g per minute) and showed decreasing lactate production in

87 tressful part of the film clip (by 2 breaths per minute) and was well matched in the respective contr

88 d into 3 groups: none, low-dose (</=5 mug/kg per minute), and high-dose (>5 mug/kg per minute).

89 per minute, 80 mug/kg per minute, 110 mug/kg per minute, and 140 mug/kg per minute) of adenosine infu

90 Mean peak oxygen consumption was 33 mL/kg per minute, and 92% of participants were New York Heart

91 ion of CPR time with a CC rate of 100 to 120 per minute, and CC fraction (percentage CPR time) during

92 e of 73 years, creatinine clearance of 62 ml per minute, and CIRS score of 8 at baseline.

93 of CPR, survival decreased linearly by 2.1% per minute, and rates of favorable neurological outcome

94 l rate during tachycardia was 170+/-21 beats per minute, and the mean left ventricular ejection fract

95 1074 individuals who took 69.3 to 82.8 steps per minute; and 5.3 per 1000 person-years (108 deaths) f

96 ement of peak oxygen consumption (Vo2 [mL/kg per minute]) and ventilatory efficiency (the VE/Vco2 slo

97 .17 mL/kg per minute [CI, 1.26 to 5.07 mL/kg per minute]), and quality of life (mean difference in Mi

98 Acute infusion of 30, 60, or 80 ng/kg per minute Ang II enhanced the endocytosis of albumin by

99 , compared with none at baseline or 10 ng/kg per minute Ang II.

100 /s, which corresponds to 0.045 million cells per minute at the designed geometry, which is over 2 ord

101 nt platform, four titrations can be obtained per minute (based on approximately 100 data points each)

102 heart rates (80.8 versus 61.7 and 68.0 beats per minute; both P<0.05).

103 mL ( P<0.001) and heart rate of 7+/-2 beats per minute (bpm) ( P<0.001).

104 percentile) baseline heart rate was 63 beats per minute (bpm) (57-71 bpm).

105 angle ( ), percent rib cage (RC %), breaths per minute (BPM), and labored breathing index (LBI) on a

106 .6 mmHg), heart rate [HR; -4.0 +/- 1.7 beats per minute (bpm)], triglycerides (-72 +/- 38.2 mg/dl), i

107 40-358; P < .01), resting HR (mean, 84 beats per minute [bpm]; 95% CI, 82-86 to 74 bpm; 95% CI, 72-76

108 Spontaneous events were infrequent (0.3 per minute), but the rate and amplitude were increased a

109 and HeLa (Km 0.32 microM and Vmax 42 pmol/mg per minute) cells.

110 9-4.7) with twice the magnitude of rotations per minute changes (130 versus 60 rotations per minute/p

111 mption (Vo2max) (mean difference, 3.17 mL/kg per minute [CI, 1.26 to 5.07 mL/kg per minute]), and qua

112 le residents had increased number of intakes per minute compared with female residents (p=.017), and

113 ast 15-minute interval (2.66 +/- 0.55 cycles per minute) compared to the baseline recording (2.81 +/-

114 Chest compression rate was 111+/-19 per minute, compression fraction was 0.70+/-0.17, and co

115 ssion rates closer to 85 to 100 compressions per minute (cpm) than nonsurvivors (absolute mean differ

116 ths (adjusted intervention effect 8.8 counts per minute [cpm]; 95% CI -18.7 to 36.3; p = 0.53).

117 reaths per minute, a heart rate of 158 beats per minute, decreased breath sounds on the left side, an

118 rological outcome (multivariable-adjusted RR per minute delay, 0.95 [95% CI, 0.91-0.99]).

119 ysis (multivariable-adjusted risk ratio [RR] per minute delay, 0.95 [95% CI, 0.93-0.98]).

120 vival at 24 hours (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.95-0.99]), and decreas

121 ased risk of ROSC (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.96-0.99]), decreased r

122 s per minute; single mutation, 134+/-8 beats per minute; double mutations, 111+/-6 beats per minute;

123 semantic categories (content-specific words) per minute during play sessions.

124 o the constrictions of several hundred cells per minute during their passage through the device.

125 ncreased number of staff positive utterances per minute, especially when residents made between 0 and

126 ntravenous infusion of adenosine (140 mug/kg per minute, FFRiv).

127 dose of 0.2 mug per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1 mug per

128 , followed by a dose of 0.1 mug per kilogram per minute for 23 hours) or placebo, with the infusion s

129 receive either supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open

130 f high-rate ventricular pacing (at 220 beats per minute for the first 4 weeks to develop HF and anoth

131 0.05 to 0.2 mug per kilogram of body weight per minute) for 24 hours or placebo in addition to stand

132 10(5) to 10(7) per flush from the toilets or per minute from the lab-scale models, and the total volu

133 Bayesian credible interval, 1.02-2.42) mL/kg per minute greater in the 2-lead device group versus con

134 s, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 1

135 ion) with resting heart rates above 82 beats per minute had a 69% (95% CI, 46%-94%) increased risk fo

136 scan cycle speed of approximately 45 full MS per minute, improving the definition of extracted LC-MS

137 talyzed the hydrolysis of 1.0 mumol of TAPTA per minute in a pH 7.40 phosphate buffer saline solution

138 proximately 10(-9) to 10(-7) mL per flush or per minute in all cases.

139 arance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), an

140 6+/-13.0 mumol per kilogram of fat-free mass per minute in the diet group and from 29.4+/-12.6 to 54.

141 rt rate of the patients was 60.7+/-9.0 beats per minute in the ivabradine group versus 70.6+/-10.1 be

142 e transients, with peaks averaging up to six per minute in the peripheral domain.

143 he ivabradine group versus 70.6+/-10.1 beats per minute in the placebo group.

144 5+/-10.4 mumol per kilogram of fat-free mass per minute in the surgery group; there was no significan

145 to 8.33) mumol per kilogram of fat-free mass per minute in the two groups, respectively, during clamp

146 as within the normal range (2.3 - 3.5 cycles per minute) in all animals in all regimens.

147 ffect of 4-week infusion of AngII (400 ng/kg per minute) in APA-KO and wild-type mice.

148 sponses to step changes (200-400 revolutions per minute) in continuous-flow left ventricular assist d

149 r treated ventricular tachycardia >250 beats per minute) in follow-up was assessed by Cox regression

150 namic response during exercise (>3.0 mm Hg/L per minute increase), with 91% sensitivity and 82% speci

151 the videos increased, the number of intakes per minute increased for residents who made one or more

152 ion (milliliters per kilogram of body weight per minute) increased more in the combination and aerobi

153 ls (0.156+/-0.133 versus 0.254+/-0.166 beats per minute/[isoproterenol ng/mL]; P<0.001).

154 as comparable when expressed in kilocalories per minute (L: 2.6 +/- 0.2 kcal/min; H: 2.9 +/- 0.3 kcal

155 have a net negative change in neurite length per minute, leading to a reduction of overall neurite le

156 .61 if society is willing to pay pound 1,800 per minute less sedentary time/day, and 0.13 probability

157 Faster rate (>200 beats per minutes), longer (>7 beats), and repetitive runs of

158 s /s), exercise capacity (-2.0 +/- 2.1 ml/kg per minute), low-back and hamstring flexibility (-4.7 +/

159 cose metabolized per kilogram of body weight per minute (Mbw) assessed during steady-state conditions

160 c from total binding measurements (in decays per minute/mm(2), DPM mm(2)) and was compared with cardi

161 A cutting throughput up to 64 cells per minute-more than 200 times faster than current metho

162 ular tachypacing (2-6 weeks at 200-240 beats per minute; n=17).

163 ebulizer temperature and 1.1 standard litres per minute nitrogen flow rate.

164 cebo, neither low-dose dopamine (2 microg/kg per minute) nor low-dose nesiritide (0.005 mug/kg per mi

165 supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen.

166 ability of swine-to-human H3N2v transmission per minute of swine contact.

167 inute, 110 mug/kg per minute, and 140 mug/kg per minute) of adenosine infusion.

168 several thousands of individual data points per minute on double-stranded DNA standard (dsDNA) sampl

169 carboplatin area under the curve >/= 4 mg/mL per minute or high-dose chemotherapy, and for pediatric

170 a dose of 15 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition

171 l heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activ

172 ar dysfunction, and a heart rate of 70 beats per minute or more.

173 f norepinephrine per kilogram of body weight per minute or the equivalent dose of another vasopressor

174 ther high-flow nasal cannulae (5 to 6 liters per minute) or nasal CPAP (7 cm of water) after extubati

175 0.025 to 0.2 mug per kilogram of body weight per minute) or placebo, for up to 48 hours or until disc

176 dentified the average of the maximum T(skin) per minute over a 30-min interval as the optimal way to

177 s of micromoles hydrogen peroxide decomposed per minute over a period of 348 s, was found to vary wit

178 ) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009 for within-group changes), whereas n

179 er minute vs 7 hours, 0.34 +/- 0.05 mm Hg/mL per minute, P = 0.005).

180 eta-blocker exposure each predicted -7 beats per minute, P<0.0001.

181 perative JET from 148+/-31 to 106+/-32 beats per minute, P<0.001, and restored sinus rhythm in 7/7 do

182 response rate from 166+/-58 to 63+/-29 beats per minute, P<0.001.

183 , P=0.08; 77.4+/-7.3 versus 78.8+/-6.0 beats per minute, P=0.50, respectively).

184 per minute; double mutations, 111+/-6 beats per minute; P<0.0001), and lower in symptomatic versus a

185 tion carriers (122+/-10 versus 137+/-9 beats per minute; P<0.0001).

186 +/-25 beats per minute versus 136+/-24 beats per minute; P<0.001) and to reduced peak stroke volume i

187 VO(2) and HR (117+/-15 versus 156+/-15 beats per minute; P<0.001) were lower in HFpEF than senior con

188 /-7.7 mL/kg per minute; UC, 23.4+/-6.0 mL/kg per minute; P<0.001).

189 sumption, 44.6+/-5.2 versus 46.3+/-5.4 mL/kg per minute; P<0.001).

190 rvedilol (308 +/- 25 versus 351 +/- 31 beats per minute; P<0.001).

191 wer peak HRs (122+/-14 versus 156+/-15 beats per minute; P<0.001).

192 low speed: 41 +/- 15 versus 33 +/- 16 bursts per minute; P<0.01) despite a reduction in mean arterial

193 +/-44 beats per minute versus 229+/-31 beats per minute; P=0.001), and longer ventriculo-atrial times

194 /mL collagen -67.7x10(2)+/-37.4x10(2) counts per minute; P=0.0014), suggesting amplification of the P

195 /-7.0 mL/kg per minute; UC, 23.9+/-6.6 mL/kg per minute; P=0.002) at 8 weeks, which persisted during

196 ess MBF than controls (2.36 versus 3.00 mL/g per minute; P=0.002).

197 ly lower in the PAH group (12.6+/-1.31 mL/kg per minute; P=0.01) and trended toward lower in the tetr

198 ygen consumption (22+/-6 versus 18+/-6 mL/kg per minute; P=0.014) and Minnesota living with HF questi

199 tetralogy of Fallot group (13.5+/-1.29 mL/kg per minute; P=0.06) compared with controls (16.7+/-1.37

200 per minute changes (130 versus 60 rotations per minute/patient, P=0.004) during the study.

201 e tolvaptan group, as compared with -3.61 ml per minute per 1.73 m(2) (95% CI, -4.08 to -3.14) in the

202 m baseline in the estimated GFR was -2.34 ml per minute per 1.73 m(2) (95% confidence interval [CI],

203 e in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m(2) (95% confidence interval [CI],

204 had a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) (P=0.75).

205 ile of suPAR levels as compared with -4.2 ml per minute per 1.73 m(2) among participants in the highe

206 p; the annual change in the eGFR was -0.9 ml per minute per 1.73 m(2) among participants in the lowes

207 and a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) at the end of the trial.

208 mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m(2) in the allopurinol group and 67

209 73 m(2) in the allopurinol group and 67.3 ml per minute per 1.73 m(2) in the placebo group.

210 erular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m(2) of body-surface area and albumi

211 ified creatinine clearance of at least 40 ml per minute per 1.73 m(2) of body-surface area and had be

212 d glomerular filtration rate [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from basel

213 rams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m(2) of body-surface area in the pre

214 of age with an estimated GFR of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 6

215 glomerular filtration rate of at least 30 ml per minute per 1.73 m(2) of body-surface area to receive

216 the prevalence of an eGFR of less than 60 ml per minute per 1.73 m(2) of body-surface area was higher

217 ated glomerular filtration rate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either

218 lomerular filtration rate [GFR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receiv

219 pment of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were anal

220 ated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m(2) of body-surface area), and risk

221 tration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m(2) of body-surface area, and diabe

222 ciliter, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m(2) of body-surface area, and evide

223 ed GFR were -0.30+/-0.66 and -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectiv

224 timated glomerular filtration rate of <30 ml per minute per 1.73 m(2) or receipt of dialysis).

225 47], respectively; mean difference, -0.10 ml per minute per 1.73 m(2) per year [95% CI, -1.18 to 0.97

226 interval {CI}, -4.11 to -2.55] and -3.23 ml per minute per 1.73 m(2) per year [95% CI, -3.98 to -2.4

227 urinol group and the placebo group (-3.33 ml per minute per 1.73 m(2) per year [95% confidence interv

228 ecrease in the iohexol-based GFR was -3.0 ml per minute per 1.73 m(2) per year with allopurinol and -

229 3 m(2) per year with allopurinol and -2.5 ml per minute per 1.73 m(2) per year with placebo (between-

230 h placebo (between-group difference, -0.6 ml per minute per 1.73 m(2) per year; 95% CI, -1.5 to 0.4).

231 of age with an estimated GFR of 25 to 44 ml per minute per 1.73 m(2) were randomly assigned in a 1:1

232 1 participants with a normal eGFR (>/= 90 ml per minute per 1.73 m(2)) at baseline had the largest su

233 ated confounders, lower eGFR (in milliliters per minute per 1.73 m(2)) was associated with an increas

234 tion, or a sustained estimated GFR of <15 ml per minute per 1.73 m(2)), a doubling of the serum creat

235 pants with a baseline eGFR of at least 60 ml per minute per 1.73 m(2), the risk of progression to chr

236 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m(2).

237 4) in the placebo group (difference, 1.27 ml per minute per 1.73 m(2); 95% CI, 0.86 to 1.68; P<0.001)

238 e remaining 363 patients (mean eGFR, 31.7 ml per minute per 1.73 m(2); median urine albumin:creatinin

239 fference in cerebral blood flow [milliliters per minute per 100 ml] per doubling of the albumin-to-cr

240 y of variance in fetal heart rate (-10 beats per minute per added mutation; P<1.0x10(-23)).

241 in live animals can exceed 1 billion events per minute per gram of colonic contents, and multiphylum

242 Gaps per minute plus static (p0.1), mean (p0.5), and peak (p0

243 NA damage propagated more than 100 kilobases per minute, reaching up to 30 megabases.

244 ontrols (59.5+/-14.4 and 35.5+/-12.8 pmol/mg per minute, respectively).

245 hing beats were 53+/-6.9 and 69+/-10.4 beats per minute, respectively, at 4 weeks.

246 gulation for the tube holder; 3) revolutions per minute (RPM) and time; 4) RCF value calculated at ei

247 icrochannel, metering chambers and revulsion per minute (RPM) control.

248 y limited by their accuracy at the nanoliter-per-minute scale.

249 at a rate of 150 standard cubic centimeters per minute (sccm).

250 hour (kg/h) (0.6 to 600 standard cubic feet per minute (scfm)).

251 Slower (</=200 beats per minute), shorter (</=7), or a single run of NSVT wer

252 - 9.3 mL/kg per minute vs 44.1 +/- 8.8 mL/kg per minute), shorter exercise duration (9.3 +/- 2.8 minu

253 r added mutation (no mutation, 143+/-5 beats per minute; single mutation, 134+/-8 beats per minute; d

254 treme bradycardia with heart rate </=4 beats per minute) superimposed on exercise up-regulation (stro

255 KD; estimated creatinine clearance, >/=60 ml per minute), the vasopressin V2-receptor antagonist tolv

256 The mean GFR was 115+/-24 ml per minute, the mean number of nephrons was 860,000+/-37

257 For each increment of 10 beats per minute, the multivariable adjusted hazard ratios in

258 nder constant and pulsatile flow at 60 beats per minute, thus yielding eight distinct testing conditi

259 ment in peak Vo2 from 14.5 (10.5-16.6) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009

260 from a maximum of 10,480 +/- 315 revolutions per minute to a minimum of 8500 +/- 380 revolutions per

261 ously sampling micro-liter volumes of sample per minute to detect dynamic changes in target analyte c

262 lary supplied by a reactant gas up to 500 mL per minute to gain a controlled atmosphere.

263 develop HF and another 4 weeks at 180 beats per minute to maintain HF).

264 ular pump, contracting, on average, 80 times per minute to propel 8000 liters of blood through body t

265 stimated creatinine clearance of 30 to 69 ml per minute to receive chlorambucil, obinutuzumab plus ch

266 e exercise at 24 weeks (EX, 26.9+/-7.7 mL/kg per minute; UC, 23.4+/-6.0 mL/kg per minute; P<0.001).

267 eak oxygen consumption (EX, 26.7+/-7.0 mL/kg per minute; UC, 23.9+/-6.6 mL/kg per minute; P=0.002) at

268 ore, 8; median creatinine clearance, 66.4 ml per minute) underwent randomization, with 216 assigned t

269 pic response (peak heart rate 111+/-25 beats per minute versus 136+/-24 beats per minute; P<0.001) an

270 ic reciprocating tachycardia (176+/-44 beats per minute versus 229+/-31 beats per minute; P=0.001), a

271 Vector magnitude counts per minute (VM CPM) and time per day spent in different

272 consumption (VO2max/kg) (37.5 +/- 9.3 mL/kg per minute vs 44.1 +/- 8.8 mL/kg per minute), shorter ex

273 course of perfusion (0 hour, 1.6 +/- 0.51 mm per minute vs 7 hours, 0.34 +/- 0.05 mm Hg/mL per minute

274 icted resting heart rate increase of 5 beats per minute was associated with a 20% increase in mortali

275 Decreased number of intakes of solid food per minute was associated with increased number of staff

276 Increased number of intakes of liquid food per minute was associated with increased number of staff

277 higher accelerometer-assessed average counts per minute was associated with lower all-cause mortality

278 The number of intakes per minute was associated with resident gender in that m

279 ardia/ventricular fibrillation >/= 240 beats per minute was equivalent to the control survival rate.

280 claims, indicating that an increase in RVUs per minute was not concentrated in a small number of hig

281 aused by ventricular tachyarrhythmias >/=240 per minute was observed in 7 and 10 patients, respective

282 s, half maximal relaxation time (RT50) at 60 per minute was prolonged by 13% in HHD and by 18% in HHD

283 n during which </=2 L of supplemental oxygen per minute was received.

284 to a flow restrictor enabling low microliter per minute water flow through a solid phase extraction (

285 depth, compression rates between 100 and 120 per minute were associated with greatest survival to hos

286 ated creatinine clearance of less than 70 ml per minute were randomly assigned to receive venetoclax-

287 ncreased number of staff positive utterances per minute when residents did not make positive utteranc

288 high cell processing speed (20 million cells per minute) which remarkably outperforms previous device

289 ric rate threshold between 185 and 200 beats per minute, which exceeds the rate tested in clinical tr

290 termined a turnover number of eight peptides per minute, which is two orders of magnitude higher than

291 reased heart rate by approximately 145 beats per minute, which was not seen in KCa3.1(-/-) mice.

292 esolution at 40 cm), normalized by 200 words per minute, which was the mean value for a group of 365

293 mpared with intravenous infusion (140 mug/kg per minute), while requiring less time and offering supe

294 deteriorated in the sham group (-13.9 words per minute) with no loss in the treated group (P = 0.02)

295 roximately 60 nt incorporated per telomerase per minute, with Km(dGTP) approximately 17 muM, indicati

296 rate (proSpy) occurs at 200 amino acids (aa) per minute, with SecA able to dissociate and rebind duri

297 inute) nor low-dose nesiritide (0.005 mug/kg per minute without bolus) enhanced decongestion or prese

298 suppression of the tachycardia to <100 beats per minute without termination within 12 hours of initia

299 e to walk at travel speeds of 3 body lengths per minute, without the need for complex on-board valves

300 cipants, compared to controls, read 46 words per minute (wpm) slower on MNRead (95% confidence interv

301 The number of correctly read words per minute (wpm) was reported.

302 national Reading Speed Test (IReST) as words per minute (wpm).

303 pared with FBP75 (eg, 2.25-mm stent, 0 beats per minute; xy sharpness, 278.2 vs 252.3; signal-to-nois